FDA hands Seattle Genetics its 5th OK for Adcetris. But can they actually sell it for frontline Hodgkin lymphoma?
As expected, the FDA has come through with their 5th approval for Seattle Genetics’ $SGEN Adcetris. And now the company can start to prove …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
